BioCentury | Jan 12, 2018
Clinical News

Innovation's Brilacidin-OM meets in Phase II for oral mucocitis

...modified intent-to-treat (mITT) population of a Phase II trial showing that thrice-daily 45 mg/15 mL Brilacidin-OM...
...endpoint of reducing the incidence of severe oral mucositis (OM) vs. placebo (42.9% vs. 60%). Brilacidin-OM...
...and time to onset of severe OM. Innovation plans to discuss next steps with FDA. Brilacidin-OM...
BioCentury | Jun 15, 2015
Clinical News

Brilacidin-OM: Phase II started

...Cellceutix began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate Brilacidin-OM oral rinse thrice daily...
...60 patients with head and neck cancer undergoing chemoradiation. Cellceutix Corp. (OTCQB:CTIX), Beverly, Mass. Product: Brilacidin-OM...
BioCentury | Nov 24, 2014
Clinical News

Brilacidin-OM: Phase II start

...Next month, Cellceutix will begin a double-blind, placebo-controlled, U.S. Phase II trial of once-daily Brilacidin-OM for...
...with head and neck cancer receiving chemotherapy and radiotherapy. Cellceutix Corp. (OTCQB:CTIX), Beverly, Mass. Product: Brilacidin-OM...
Items per page:
1 - 3 of 3